Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Dealing with an eye toward dry eye
February 2017
SHARING OPTIONS:

TEL AVIV, Israel—In late 2016, BioLineRx Ltd. inked an exclusive, worldwide agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. for the in-licensing of a novel anti-inflammatory treatment for dry eye syndrome (DES). BL-1230 is a potent, selective cannabinoid receptor type 2 agonist developed by Prof. Raphael Mechoulam from the Department of Medicinal Chemistry and Natural Products at the Faculty of Medicine of the Hebrew University. In preclinical studies in three ocular inflammatory models, BL-1230 eye drops have shown significant anti-inflammatory activity.
 
“Inflammation is recognized as both a cause and consequence of DES and is a primary target in assessment and clinical treatment. BL-1230 not only targets inflammation via an immunomodulatory pathway that differs from current treatment options, but also may induce analgesic effects. We therefore hope that this drug will have a beneficial therapeutic effect as compared to available treatments,” said Philip Serlin, CEO of BioLineRx.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.